TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00733135

Intervention type: DEVICE
Group type: OTHER
Intervention: SilverHawk™ LS-C, TurboHawk™ LS-C, TurboHawk™ LX-C plaque excision systems and SpiderFX™ embolic protection device
Description: Catheter-based excision of moderate to severely calcified plaque located in the SFA and/or popliteal artery.
Study: NCT03084913

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plant- based, olive oil diet
Description: used as part of daily diet, followed for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant- based, olive oil diet
Description: used as part of daily diet, followed for 8 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prostate Cancer Foundation diet
Description: followed for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prostate Cancer Foundation diet
Description: followed for 8 weeks
Study: NCT00534404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patches
Description: Participants will wear nicotine patches.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patches
Description: Participants will wear nicotine patches.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Description: Participants receiving telephone counseling will receive five phone calls over a 2-month period to discuss their personal smoking cessation plan.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: iQuit Smoking website
Description: Participants will access the Project Quit (iQuit Smoking) website.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iQuit Smoking website
Description: Participants will access the Project Quit (iQuit Smoking) website.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: iQuit Smoking website
Description: Participants will access the Project Quit (iQuit Smoking) website.
Study: NCT03077802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Seldinger technique, Inexperienced group
Description: This is a technique for central venous catheterization. We will use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel. This technique will be performed by inexperienced practitioners who are junior residents and have experience of less than 50 central venous catheterizations in both techniques.
Study: NCT01039610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK945237
Description: Dose detailed in Arm description
Study: NCT03612349

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Experimental Tobacco Marketplace Task
Description: Participants will select tobacco products from an Experimental Online Tobacco Marketplace under both marketplace conditions.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Experimental Tobacco Marketplace Task
Description: Participants will select tobacco products from an Experimental Online Tobacco Marketplace under both marketplace conditions.
Study: NCT03349983

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Brachyury/ FPV-Brachyury
Description: Two priming doses of MVA-BN-Brachyury followed by boost doses of FPV-Brachyury monthly for 6 months
Study: NCT04993066

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GentleMax Pro Plus
Description: The GentleMax Pro Plus laser system to be used in this study received 510(k) market clearance from the U.S. Food and Drug Administration (FDA) under K201111 on May 26, 2020
Study: NCT00811928

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Posaconazole
Description: 40 mg/mL; 200 mg (5 mL) TID~Treatment was continued with each cycle of chemotherapy until:~* The onset of a proven or probable diagnosis of invasive fungal infection (IFI)~* 3 chemotherapy cycles or~* Total treatment duration up to 12 weeks (84 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: 50 mg/capsule (2 capsules), 150 mg/capsule (2 capsules);~400 mg QD~Treatment was continued with each cycle of chemotherapy until:~* The onset of a proven or probable diagnosis of invasive fungal infection (IFI)~* 3 chemotherapy cycles or~* Total treatment duration up to 12 weeks (84 days)
Study: NCT01039610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK945237
Description: Dose detailed in Arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK945237
Description: Dose detailed in Arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK945237
Description: Dose detailed in Arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: matching placebo tablet
Study: NCT01933126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCG injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00661024

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: intraoperative RLN visualization
Description: intraoperative RLN visualization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraoperative neuromonitoring of the RLN
Description: IONM
Study: NCT01767077

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Butter oil
Description: Daily intake of 40 g butter oil

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cream
Description: Daily intake of 100 g cream (40%)
Study: NCT03077802

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Seldinger technique, Inexperienced group
Description: This is a technique for central venous catheterization. The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel. This technique will be performed by inexperienced practitioners who are junior residents and have experience of less than 50 central venous catheterizations in both techniques.
Study: NCT04534101

Intervention type: BEHAVIORAL
Intervention: Virtual Reality Mindfulness
Description: This study is designed to test the feasibility, acceptability and effectiveness of VR mindfulness in patients as they undergo various medical therapies to treat their acute or chronic conditions.

Intervention type: BEHAVIORAL
Intervention: Virtual Reality Mindfulness
Description: This study is designed to test the feasibility, acceptability and effectiveness of VR mindfulness in patients as they undergo various medical therapies to treat their acute or chronic conditions.
Study: NCT02844335

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryosurgery
Description: Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK immunotherapy
Description: Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
Study: NCT03116542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diagnostic (18F-FLT PET/CT)
Description: The tracer compound \[F-18\] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours.
Study: NCT01891344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral rucaparib
Description: 600 mg BID
Study: NCT01359605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varespladib methyl
Description: 500 mg oral suspension
Study: NCT01198457

Intervention type: DRUG
Intervention: Clodronate (Bonefos, BAY94-8393)
Description: Random group of patients in oncology clinic
Study: NCT02816203

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemostatic Intra-Uterine suction cup
Description: The hemostatic intra-uterine suction cup is introduced to the uterine cavity and a negative pressure is applied into the device.
Study: NCT01414205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants were administered obinutuzumab either at 1000 mg or 2000 mg on Day 1, 8, 15 of Cycle 1 and then on Day 1 of each 21 day cycles for up to 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants were administered obinutuzumab either at 1000 mg or 2000 mg on Day 1, 8, 15 of Cycle 1 and then on Day 1 of each 21 day cycles for up to 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Participants were administered corticosteroids IV prior to the initial dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Participants were administered corticosteroids IV prior to the initial dose.
Study: NCT02211118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal dexemdetomidine (IN-DEX)
Study: NCT02767479

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rabeprazole-based regimen
Description: This group is treated with rabeprazole 10 mg bid, AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole^based regimen
Description: This group is treated with esomeprazole 20 mg bid , AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
Study: NCT02933567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CSC OnDemand
Description: CSC OnDemand is a multifaceted online learning product that includes four levels: 1) an online readiness tool and CSC Learning Hub; 2) dynamic multimedia core curriculum on first episode psychosis and CSC; 3) live faculty-led online courses; and 4) ongoing support, including an online community of practice to support peer-to-peer learning.
Study: NCT00054691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iressa
Description: 250 mg by mouth daily
Study: NCT03077802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long-axis technique
Description: Ultrasound probe is placed parallel to the vessel trajectories and needle is advanced using in-plane approach.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long-axis technique
Description: Ultrasound probe is placed parallel to the vessel trajectories and needle is advanced using in-plane approach.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Long-axis technique
Description: Ultrasound probe is placed parallel to the vessel trajectories and needle is advanced using in-plane approach.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Long-axis technique
Description: Ultrasound probe is placed parallel to the vessel trajectories and needle is advanced using in-plane approach.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short-axis technique
Description: Ultrasound probe is placed vertical to the vessel trajectories and needle is advanced using out-of-plane approach.
Study: NCT01696279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum Carbonate
Description: Lanthanum Carbonate 1500 mg to 3000 mg powder will be administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate
Description: Calcium carbonate will be administered orally at a total daily dose based on standard clinical practice. The total daily dose may be adjusted as appropriate, until the target serum phosphorus level is achieved or until a maximum daily dose of 6500 mg is reached.
Study: NCT03077802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short-axis technique
Description: Ultrasound probe is placed vertical to the vessel trajectories and needle is advanced using out-of-plane approach.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Short-axis technique
Description: Ultrasound probe is placed vertical to the vessel trajectories and needle is advanced using out-of-plane approach.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Short-axis technique
Description: Ultrasound probe is placed vertical to the vessel trajectories and needle is advanced using out-of-plane approach.
Study: NCT02029833

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular Canola Oil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Oleic Canola Oil

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Western Type Diet - Common Dietary Oils
Study: NCT04214626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Induction Chemotherapy: 375mg/m2, Intravenous administration on day 0 of each 3-week cycle until disease progression, stable disease after 2 cycles treatment, partial response after 4 cycles treatment or unacceptable toxicity develops, up to 6 cycles.~Maintenance Treatment for patients with CR after 6 cycles: Rituximab, 375mg/m2, Intravenous administration on day 0 repeated every 3 weeks until disease progression or unacceptable toxicity develops, up to 2 cycles (Total 8 cycles).
Study: NCT04028076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peers Supporting Health-Literacy, Self Efficacy, Advocacy and Adherence
Description: An 8-week culturally appropriate educational behavioral intervention that consists of structured group diabetes education and follow-up peer support with PAs. There will be 3 separate group education sessions led by a physician, AA pharmacist and AA diabetes educator. All PAs will attend each group session to learn together with their PBs and build social interactions. Weeks 1 and 2 consist of 2-hour group education between the participants and diabetes educator, and participants and pharmacist, respectively. Pre-test intervention data including A1c will be collected in Week 1. In Weeks 3-7, PAs will deliver the intervention content to PBs over the phone as well as help them set a goal towards getting healthy. An existing video/text messaging app, called WhatsApp® will be offered as an option to use to further enhance PA-PB interaction.
Study: NCT04723381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: web based education
Description: Expert support and consultancy were received for the design and preparation of the web page.
Study: NCT04425265

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasma radiofrequency ablation
Description: Under the guidance of nasal endoscope, the nasopharyngeal tumor and its sufficient safety margin are completely removed through the bilateral nasal cavity. Then investigators use plasma radiofrequency ablation at low temperature to ablate the tumor tissue and normal tissue of the margin along the upper and lower surgical margin until no obvious tumor remained under the naked eye.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocautery block resection
Description: Under the guidance of nasal endoscope, the nasopharyngeal tumor and its sufficient safety margin are continuously and completely removed through the bilateral nasal cavity. Then investigators separate the posterior part of the nasal cavity and the top wall of the nasopharynx along the bone of the nasopharyngeal fornix, cut the pharyngeal suture, and cut the two sides along the edge of the carina, and then merge along the anterior vertebral muscle surface to the midline incision. Along the the soft palate under the inferior margin, investigators horizontally cut the mucosa of the posterior wall of the nasopharynx, and completely frees the entire soft tissue of the posterior wall of the nasopharynx.
Study: NCT04798547

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Short Myotomy
Description: Evaluation of short length myotomy
Study: NCT03115021

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tDCS
Description: Sham tDCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tDCS condition and the electrodes placement as well.
Study: NCT04798547

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard Length Myotomy
Description: Standard Length Myotomy
Study: NCT01108601

Intervention type: DRUG
Group type: OTHER
Intervention: Ringer's Lactate (0.03% Ciprofloxacin)
Description: For each patient, only one ear will receive the Ringer's Lactate solution. The other ear will act as a control. To ensure adequate delivery of the solution to the middle ear, a small pressure equalizing tube will be inserted under local anesthesia before commencement of chemotherapy treatment. The patient will be instructed to administer four drops of RL solution to the experimental ear twice a day during their chemotherapy treatment.
Study: NCT03959293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg by 1-hour IV infusion - Every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500 mg by 1-hour IV infusion - Every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 75 mg by 1-hour IV infusion - Every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI Protocol
Description: * Irinotecan: 180 mg/m² by 2-hour IV infusion,~* Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2-hours IV infusion,~* 5-FU bolus: 400 mg/m² by 10-minutes IV bolus,~* Continuous 5-FU: 2400 mg/m² by 46-hour IV infusion
Study: NCT03959293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI Protocol
Description: * Irinotecan: 180 mg/m² by 2-hour IV infusion,~* Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) by 2-hours IV infusion,~* 5-FU bolus: 400 mg/m² by 10-minutes IV bolus,~* Continuous 5-FU: 2400 mg/m² by 46-hour IV infusion
Study: NCT01216527

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neo-adjuvant Chemoradiotherapy followed by Surgery
Description: 1. Radiotherapy combined with concomitant chemotherapy:~   Radiotherapy Program:External radiation with a total dose of 40.0Gy is given in 20 fractions of 2.0Gy,5 fractions a week.~   neo-chemotherapy program: Vinorelbine 25mg/m2, IV (in the vein) on day 1 and day 8 of each 21 day cycle. Cisplatin 75mg/m2,IV DRIP on day 1 of each 21 day cycle;or Cisplatin 25mg/m2,IV DRIP on day 1 to day 4 of each 21 day cycle.~   Number of cycles:two~2. surgery:Mckeown Modification Surgery and total two-field lymphadenectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: two field lymphadenectomy
Study: NCT04372667

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community score card approach
Description: The CSC intervention is a participatory community approach. Health care workers (HCWs), PMTCT clients identified the issues that most impacted PMTCT service quality and uptake, and came together to implement actions for improvement. The core implementation strategy is using dialogue in a participatory forum that engages both service users and service providers. The CSC consists of five core phases, repeated on a regular basis (called rounds), for the life of the project. The five core phases include:~1. Phase I: Planning and preparation~2. Phase II: Conducting the Score Card with the community~3. Phase III: Conducting the Score Card with service providers~4. Phase IV: Interface meeting and action planning~5. Phase V: Action plan implementation and follow-up
Study: NCT02461108

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Subsidy
Description: Frame the price difference as a 10% subsidy on nutritious food items.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tax
Description: Frame the price difference as a 10% tax on less nutritious food items.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tax and subsidy
Description: Frame the price difference as a 5% tax on less nutritious food items and a 5% subsidy on nutritious food items, creating a 10% relative price difference between the types of foods.
Study: NCT01647412

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth Hormone
Description: Humatrope will be administered daily to patients in a dose of .18-.20 mg/kg/week.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutraceutical Combination

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nutraceutical Combination

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exclusion Diet
Description: Patients on the exclusion diet will adhere from consumption of all grain, corn, dairy, and carrageenan containing products.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exclusion Diet
Description: Patients on the exclusion diet will adhere from consumption of all grain, corn, dairy, and carrageenan containing products.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Growth Hormone
Study: NCT04541056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Management Training (GMT)
Description: The manual comprises an introduction to GMT for the survivors of ALL, and a detailed session structure incorporating cognitive and behavioral tasks. The GMT program involves teaching the participants about goals, attention slips and how to manage these, how to review and prioritize goals (e.g., Stop, Think, Organize, Plan), and how to keep goals in mind (e.g., using analogies such as the mental blackboard). Each session will follow the same general format; namely, facility-delivered presentations, flipchart discussions, group activities and homework.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain Health Workshop (BHW)
Description: BHW is a psycho-educative control condition, and is typically part of psycho-educative Acquired Brain Injury (ABI) rehabilitation programs, but adjusted for the ALL group of participants. The psycho-educative control condition BHW will be matched GMT for amount of training and therapist contact. Homework assignment and in-session tasks included readings, brain games, puzzles, and practical exercises such as logging sleep.